1h Free Analyst Time
The publisher has been monitoring the schizophrenia drugs market and it is poised to grow by $957.50 mn during 2021-2025, progressing at a CAGR of 2.06% during the forecast period. The report on the schizophrenia drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing expenditure on prescription drugs and increasing awareness programs.
The schizophrenia drugs market analysis includes the drug class segment and geographic landscape.
The schizophrenia drugs market is segmented as below:
By Drug Class
- Second-generation antipsychotic drugs
- Third-generation antipsychotic drugs
- First-generation antipsychotic drugs
By Geographical Landscape
- North America
- Europe
- Asia
- ROW
This study identifies the enhanced next-generation products as one of the prime reasons driving the schizophrenia drugs market growth during the next few years.
The report on schizophrenia drugs market covers the following areas:
- Schizophrenia drugs market sizing
- Schizophrenia drugs market forecast
- Schizophrenia drugs market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading schizophrenia drugs market vendors that include AbbVie Inc., Alkem Laboratories Ltd., Alkermes Plc, AstraZeneca Plc, Biogen Inc., Boehringer Ingelheim International GmbH, Dr. Reddys Laboratories Ltd., Eli Lilly and Co., Johnson and Johnson Inc., and Otsuka Holdings Co. Ltd. Also, the schizophrenia drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary- Market Overview
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2020
- Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Drug class
- Market segments
- Comparison by Drug class
- Second-generation antipsychotic drugs - Market size and forecast 2020-2025
- Third-generation antipsychotic drugs - Market size and forecast 2020-2025
- First-generation antipsychotic drugs - Market size and forecast 2020-2025
- Market opportunity by Drug class
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2020-2025
- Europe - Market size and forecast 2020-2025
- Asia - Market size and forecast 2020-2025
- ROW - Market size and forecast 2020-2025
- Key leading countries
- Market opportunity By Geographical Landscape
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- AbbVie Inc.
- Alkem Laboratories Ltd.
- Alkermes Plc
- AstraZeneca Plc
- Biogen Inc.
- Boehringer Ingelheim International GmbH
- Dr. Reddys Laboratories Ltd.
- Eli Lilly and Co.
- Johnson and Johnson Inc.
- Otsuka Holdings Co. Ltd.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
List of Exhibits
- Key Finding 1
- Key Finding 2
- Key Finding 3
- Key Finding 5
- Key Finding 6
- Key Finding 7
- Key Finding 8
- Parent market
- Market characteristics
- Offerings of vendors included in the market definition
- Market segments
- Global - Market size and forecast 2020 - 2025 ($ million)
- Global market: Year-over-year growth 2020 - 2025 (%)
- Five forces analysis 2020 & 2025
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition - Five forces 2020
- Drug class - Market share 2020-2025 (%)
- Comparison by Drug class
- Second-generation antipsychotic drugs - Market size and forecast 2020-2025 ($ million)
- Second-generation antipsychotic drugs - Year-over-year growth 2020-2025 (%)
- Third-generation antipsychotic drugs - Market size and forecast 2020-2025 ($ million)
- Third-generation antipsychotic drugs - Year-over-year growth 2020-2025 (%)
- First-generation antipsychotic drugs - Market size and forecast 2020-2025 ($ million)
- First-generation antipsychotic drugs - Year-over-year growth 2020-2025 (%)
- Market opportunity by Drug class
- Customer landscape
- Market share By Geographical Landscape 2020-2025 (%)
- Geographic comparison
- North America - Market size and forecast 2020-2025 ($ million)
- North America - Year-over-year growth 2020-2025 (%)
- Europe - Market size and forecast 2020-2025 ($ million)
- Europe - Year-over-year growth 2020-2025 (%)
- Asia - Market size and forecast 2020-2025 ($ million)
- Asia - Year-over-year growth 2020-2025 (%)
- ROW - Market size and forecast 2020-2025 ($ million)
- ROW - Year-over-year growth 2020-2025 (%)
- Key leading countries
- Market opportunity By Geographical Landscape ($ million)
- Impact of drivers and challenges
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- AbbVie Inc. - Overview
- AbbVie Inc. - Product and service
- AbbVie Inc. - Key offerings
- AbbVie Inc. - Key customers
- AbbVie Inc. - Segment focus
- Alkem Laboratories Ltd. - Overview
- Alkem Laboratories Ltd. - Product and service
- Alkem Laboratories Ltd. - Key offerings
- Alkem Laboratories Ltd. - Key customers
- Alkem Laboratories Ltd. - Segment focus
- Alkermes Plc - Overview
- Alkermes Plc - Business segments
- Alkermes Plc - Key offerings
- Alkermes Plc - Key customers
- Alkermes Plc - Segment focus
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Product and service
- AstraZeneca Plc - Key offerings
- AstraZeneca Plc - Key customers
- AstraZeneca Plc - Segment focus
- Biogen Inc. - Overview
- Biogen Inc. - Business segments
- Biogen Inc. - Key offerings
- Biogen Inc. - Key customers
- Biogen Inc. - Segment focus
- Boehringer Ingelheim International GmbH - Overview
- Boehringer Ingelheim International GmbH - Business segments
- Boehringer Ingelheim International GmbH - Key offerings
- Boehringer Ingelheim International GmbH - Key customers
- Boehringer Ingelheim International GmbH - Segment focus
- Dr. Reddys Laboratories Ltd. - Overview
- Dr. Reddys Laboratories Ltd. - Business segments
- Dr. Reddys Laboratories Ltd. - Key offerings
- Dr. Reddys Laboratories Ltd. - Key customers
- Dr. Reddys Laboratories Ltd. - Segment focus
- Eli Lilly and Co. - Overview
- Eli Lilly and Co. - Business segments
- Eli Lilly and Co. - Key offerings
- Eli Lilly and Co. - Key customers
- Eli Lilly and Co. - Segment focus
- Johnson and Johnson Inc. - Overview
- Johnson and Johnson Inc. - Business segments
- Johnson and Johnson Inc. - Key offerings
- Johnson and Johnson Inc. - Key customers
- Johnson and Johnson Inc. - Segment focus
- Otsuka Holdings Co. Ltd. - Overview
- Otsuka Holdings Co. Ltd. - Business segments
- Otsuka Holdings Co. Ltd. - Key offerings
- Otsuka Holdings Co. Ltd. - Key customers
- Otsuka Holdings Co. Ltd. - Segment focus
- Currency conversion rates for US$
- Research Methodology
- Validation techniques employed for market sizing
- Information sources
- List of abbreviations
Executive Summary
The publisher recognizes the following companies as the key players in the global schizophrenia drugs market: AbbVie Inc., Alkem Laboratories Ltd., Alkermes Plc, AstraZeneca Plc, Biogen Inc., Boehringer Ingelheim International GmbH, Dr. Reddys Laboratories Ltd., Eli Lilly and Co., Johnson and Johnson Inc., and Otsuka Holdings Co. Ltd.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is enhanced next-generation products.'
According to the report, one of the major drivers for this market is the increasing expenditure on prescription drugs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Alkem Laboratories Ltd.
- Alkermes Plc
- AstraZeneca Plc
- Biogen Inc.
- Boehringer Ingelheim International GmbH
- Dr. Reddys Laboratories Ltd.
- Eli Lilly and Co.
- Johnson and Johnson Inc.
- Otsuka Holdings Co. Ltd.
